Rituximab Plus Cyclophosphamide in Treating Patients With Indolent Stage III or Stage IV Non-Hodgkin's Lymphoma

Withdrawn before enrolling · Phase 2

Conditions studied: Lymphoma

In brief

RATIONALE: Monoclonal antibodies can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy and monoclonal antibody therapy may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of rituximab plus cyclophosphamide in treating patients who have indolent stage III or stage IV non-Hodgkin's lymphoma.

Key facts

Study ID

NCT00003605

Run by

Hoag Memorial Hospital Presbyterian

People needed

0

Starts

1998-05-01

Expected to finish

2000-01-01

Last updated by the study team

2015-08-19

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Hoag Memorial Hospital Presbyterian — Newport Beach, California, United States
• Bloomington Hospital — Bloomington, Indiana, United States
• St. Joseph Regional Cancer Center — Bryan, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.